ME01310B - Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa - Google Patents

Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa

Info

Publication number
ME01310B
ME01310B MEP-2008-775A MEP77508A ME01310B ME 01310 B ME01310 B ME 01310B ME P77508 A MEP77508 A ME P77508A ME 01310 B ME01310 B ME 01310B
Authority
ME
Montenegro
Prior art keywords
diabetes
ppar
alpha
treatment
carboxylic acid
Prior art date
Application number
MEP-2008-775A
Other languages
English (en)
French (fr)
Inventor
Alfred Binggeli
Markus Boehringer
Uwe Grether
Hans Hilpert
Hans-Peter Maerki
Markus Meyer
Peter Mohr
Fabienne Ricklin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ME01310B publication Critical patent/ME01310B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Ovaj pronalazak se odnosi na jedinjenja formule (I) u kojoj su R 1  do R 7  definisani kao što je dato u opisu i zahtevima, i na njihove farmaceutski prihvatljive soli i estre. Ova jedinjenja su primenljiva za lečenje bolesti kao što je dijabetes.
MEP-2008-775A 2001-05-15 2002-05-06 Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa ME01310B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111745 2001-05-15
PCT/EP2002/004962 WO2002092084A1 (en) 2001-05-15 2002-05-06 Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes

Publications (1)

Publication Number Publication Date
ME01310B true ME01310B (me) 2011-10-10

Family

ID=8177436

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2008-775A ME01310B (me) 2001-05-15 2002-05-06 Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa

Country Status (39)

Country Link
US (1) US6642389B2 (me)
EP (1) EP1392295B1 (me)
JP (2) JP4330883B2 (me)
KR (1) KR100654516B1 (me)
CN (1) CN100356917C (me)
AR (1) AR035892A1 (me)
AT (1) ATE327753T1 (me)
AU (1) AU2002342244B2 (me)
BG (1) BG66316B1 (me)
BR (1) BRPI0209821B1 (me)
CA (1) CA2445145C (me)
CY (1) CY1105160T1 (me)
CZ (1) CZ20033037A3 (me)
DE (1) DE60211891T2 (me)
DK (1) DK1392295T3 (me)
EC (1) ECSP034848A (me)
EG (1) EG25755A (me)
ES (1) ES2264482T3 (me)
GT (1) GT200200085A (me)
HK (1) HK1067534A1 (me)
HR (1) HRP20030889B1 (me)
HU (1) HU230224B1 (me)
IL (2) IL158589A0 (me)
JO (1) JO2282B1 (me)
MA (1) MA27025A1 (me)
ME (1) ME01310B (me)
MX (1) MXPA03010435A (me)
MY (1) MY136761A (me)
NO (1) NO333833B1 (me)
NZ (1) NZ529033A (me)
PA (1) PA8544901A1 (me)
PE (1) PE20021152A1 (me)
PL (1) PL208074B1 (me)
PT (1) PT1392295E (me)
RU (1) RU2278859C2 (me)
SI (1) SI1392295T1 (me)
SK (1) SK287842B6 (me)
WO (1) WO2002092084A1 (me)
ZA (1) ZA200308538B (me)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152979A0 (en) * 2000-05-26 2003-06-24 Nippon Shinyaku Co Ltd Heterocyclic compounds
ME01310B (me) * 2001-05-15 2011-10-10 Hoffmann La Roche Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa
EP1425029A4 (en) 2001-08-10 2006-06-07 Palatin Technologies Inc PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
EP1480642B1 (en) 2002-02-25 2008-11-26 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
MXPA05002115A (es) * 2002-08-30 2005-05-23 Hoffmann La Roche Compuestos novedosos de 2-ariltiazol como agonistas de pparalfa y ppargama.
AR041481A1 (es) 2002-10-07 2005-05-18 Hoffmann La Roche Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar
RS20050426A (en) * 2002-11-15 2008-04-04 Cadila Healthcare Limited, Substituted aralkyl derivatives
CN100343250C (zh) * 2002-11-25 2007-10-17 霍夫曼-拉罗奇有限公司 吲哚衍生物
US7268157B2 (en) * 2002-11-26 2007-09-11 Shenzhen Chipscreen Biosciences, Ltd. Substituted arylalcanoic acid derivatives as PPAR pan agonists with potent antihyperglycemic and antihyperlipidemic activity
FR2849849B1 (fr) 2003-01-13 2006-08-04 Merck Sante Sas Nouveaux acides carboxyliques et derives pour le traitement et la prevention du diabete et des dyslipemies
US7968548B2 (en) * 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
US7262303B2 (en) * 2003-09-29 2007-08-28 Hoffman-La Roche Inc. Process for the production of chiral propionic acid derivatives
JP2007509998A (ja) 2003-11-05 2007-04-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｐｐａｒ活性化剤としてのベンズ環付加された化合物
NZ546444A (en) * 2003-11-05 2009-09-25 Hoffmann La Roche Phenyl derivatives as PPAR agonists
WO2005056536A1 (en) * 2003-12-10 2005-06-23 Ranbaxy Laboratories Limited Antidiabetic agents which exhibit activity against ppar
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
DE602005015962D1 (de) 2004-05-03 2009-09-24 Hoffmann La Roche Indolylderivate als liver-x-rezeptormodulatoren
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
CN100436430C (zh) * 2004-05-24 2008-11-26 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的烷酰基取代的酪氨酸衍生物
WO2006108491A1 (en) * 2005-04-11 2006-10-19 Dsm Fine Chemicals Austria Nfg Gmbh & Co Kg Improved process for preparing oxazole nitriles
US20060241073A1 (en) * 2005-04-20 2006-10-26 Wanders Ronaldus J A Means and methods for counteracting fatty acid accumulation
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR100847780B1 (ko) * 2006-10-26 2008-07-23 재단법인서울대학교산학협력재단 2-에톡시프로피온산 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 유효성분으로함유하는 당뇨병 예방 및 치료제
KR20080082541A (ko) * 2007-03-07 2008-09-11 동아제약주식회사 퍼옥시좀 증식자-활성화 감마 수용체를 조절하는 신규한페닐프로판산 유도체의 제조방법 및 약학적 용도
DK2100604T3 (da) * 2008-03-10 2012-07-23 Nestec Sa Dicarboxylsyrer med medium kæde og deres derivater og metaboliske lidelser
JP2011520890A (ja) * 2008-05-15 2011-07-21 メルク・シャープ・エンド・ドーム・コーポレイション オキサゾロベンゾイミダゾール誘導体
CA2747309C (en) 2008-12-23 2023-09-26 F. Hoffmann-La Roche Ag Structured testing method for diagnostic or therapy support of a patient with a chronic disease and devices thereof
PE20120421A1 (es) * 2009-01-23 2012-05-04 Hoffmann La Roche Composicion farmaceutica que comprende aleglitazar
CN101805337B (zh) * 2009-02-13 2012-05-23 天津药物研究院 一类含脯氨酸和异恶唑骨架的化合物、其制备方法和用途
US8450496B2 (en) * 2009-03-24 2013-05-28 Hoffman-La Roche Inc. Process for the preparation of propionic acid derivatives
PL2585452T3 (pl) 2009-12-07 2016-03-31 Hoffmann La Roche Sposób wytwarzania pochodnych kwasu propionowego
CN102351852B (zh) * 2011-08-23 2014-06-18 上海交通大学 苯并呋喃类化合物及其制备方法、用途
WO2013181384A1 (en) 2012-05-31 2013-12-05 Ratiopharm Gmbh Solid state forms of aleglitazar sodium
RU2015110641A (ru) * 2012-09-12 2016-11-10 Ф. Хоффманн-Ля Рош Аг Твердые формы (s)-2-метокси-3-{4-[2-(5-метил-2-фенилоксазол-4-ил)-этокси]-бензо[b]тиофен-7-ил}-пропионовой кислоты и ее солей
EP3402482A1 (en) 2015-11-18 2018-11-21 H. Hoffnabb-La Roche Ag Aleglitazar for the treatment of diabetic kidney disease
WO2018002215A1 (en) 2016-06-30 2018-01-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
WO2020156683A1 (en) 2019-02-01 2020-08-06 F. Hoffmann-La Roche Ag Aleglitazar for use in the treatment or prevention of major adverse cardiac events
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
IL310176A (en) * 2021-08-13 2024-03-01 Alebund Pharmaceuticals Hong Kong Ltd Deuterated compounds
WO2024100051A1 (en) 2022-11-08 2024-05-16 Genfit Ppar-alpha/gamma agonist for use in the treatment of liver failure

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4011326A (en) 1975-07-29 1977-03-08 Merck & Co., Inc. 2-Substituted oxazolo[4,5-b]pyridine anti-inflammatory agents
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
EP0648212B1 (en) 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
PT1027043E (pt) 1996-12-10 2005-02-28 Bristol Myers Squibb Co Benzodioxole benzofurano di-hidrobenzofurano e benzodioxano como agentes melatonergicos
DE19711616A1 (de) * 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6121397A (en) 1997-07-14 2000-09-19 Xerox Corporation Polymerization processes using oligomeric compound, monomer and surfactant
HN1998000118A (es) 1997-08-27 1999-02-09 Pfizer Prod Inc 2 - aminopiridinas que contienen sustituyentes de anillos condensados.
ES2200248T3 (es) 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
GB9817118D0 (en) * 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
DK1078923T3 (da) 1999-08-02 2006-07-10 Hoffmann La Roche Fremgangsmåde til fremstilling af benzothiophenderivater
WO2002016331A1 (en) * 2000-08-23 2002-02-28 Eli Lilly And Company Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
ME01310B (me) * 2001-05-15 2011-10-10 Hoffmann La Roche Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa

Also Published As

Publication number Publication date
IL158589A (en) 2010-11-30
SK287842B6 (sk) 2011-12-05
DE60211891T2 (de) 2007-05-24
ZA200308538B (en) 2005-04-26
BRPI0209821B1 (pt) 2016-09-27
DE60211891D1 (de) 2006-07-06
US6642389B2 (en) 2003-11-04
AU2002342244B2 (en) 2005-06-16
NO20035086L (no) 2003-11-14
PL367087A1 (en) 2005-02-21
RU2278859C2 (ru) 2006-06-27
PL208074B1 (pl) 2011-03-31
PT1392295E (pt) 2006-09-29
JP2004529174A (ja) 2004-09-24
KR100654516B1 (ko) 2006-12-05
CN1509173A (zh) 2004-06-30
MXPA03010435A (es) 2004-03-09
BG66316B1 (bg) 2013-04-30
MA27025A1 (fr) 2004-12-20
HU230224B1 (hu) 2015-10-28
ES2264482T3 (es) 2007-01-01
JP2009138011A (ja) 2009-06-25
HRP20030889A2 (en) 2005-08-31
EP1392295A1 (en) 2004-03-03
ATE327753T1 (de) 2006-06-15
CA2445145A1 (en) 2002-11-21
HK1067534A1 (en) 2005-04-15
GT200200085A (es) 2003-01-16
DK1392295T3 (da) 2006-10-02
MY136761A (en) 2008-11-28
HUP0400992A2 (hu) 2004-08-30
KR20030096397A (ko) 2003-12-24
NO20035086D0 (no) 2003-11-14
PE20021152A1 (es) 2003-02-07
EG25755A (en) 2012-06-26
NO333833B1 (no) 2013-09-30
BR0209821A (pt) 2004-06-01
JO2282B1 (en) 2005-09-12
WO2002092084A1 (en) 2002-11-21
RU2003134150A (ru) 2005-06-10
CA2445145C (en) 2008-10-14
US20030055265A1 (en) 2003-03-20
BG108362A (bg) 2005-03-31
IL158589A0 (en) 2004-05-12
CN100356917C (zh) 2007-12-26
SK13852003A3 (en) 2004-10-05
PA8544901A1 (es) 2003-01-24
NZ529033A (en) 2005-06-24
CZ20033037A3 (cs) 2004-06-16
HUP0400992A3 (en) 2007-11-28
HRP20030889B1 (en) 2011-10-31
EP1392295B1 (en) 2006-05-31
SI1392295T1 (sl) 2006-10-31
JP4330883B2 (ja) 2009-09-16
ECSP034848A (es) 2003-12-24
AR035892A1 (es) 2004-07-21
CY1105160T1 (el) 2009-11-04

Similar Documents

Publication Publication Date Title
ME01310B (me) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa
CY1110969T1 (el) 5-υποκατεστημενα-2-φαινυλαμινο-βενζαμιδια ως αναστολεiς μεκ
HRP20050663A2 (en) Malonamide derivatives as gamma-secretase inhibitors
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
HRP20050308A2 (en) Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists
NO20064982L (no) 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav
ATE357453T1 (de) Comt-inhibitoren
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
PE20040916A1 (es) Diamidas de acido pirimidin-4,6-dicarboxilico como inhibidores selectivos de mmp-13
HK1050141A1 (en) Inhibitor for 20-hete-yielding enzyme
ATE265423T1 (de) Neue phenylheteroalkylamin-derivate
CO5660084A1 (es) Nuevos derivados de fenilheteroalquilamina, proceso para su prepraracion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia
YU89903A (sh) Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa i -gama aktivatori u lečenju dijabetesa
DK1042297T3 (da) Carboxylsyresubstituerede heterocykliske forbindelser som metalloproteinaseinhibitorer
ECSP034536A (es) Derivados de acido propionico